+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Basal Insulin (Long-Acting Insulin) Market - Growth, Trends, and Forecast (2012 - 2024)

  • ID: 4758275
  • Report
  • February 2019
  • Region: Global
  • 100 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Biocon
  • Eli Lilly
  • Exir
  • Julphar
  • Novo Nordisk AS
  • Sanofi Aventis
  • MORE
Market Overview

The global basal insulin market is expected to register a CAGR of 8.2% during the forecast period of 2019–2024, the market is estimated to reach USD 11.4 billion by 2019.

Diabetes is generally considered as a lifestyle disease. Over time, incidences of the disease have increased, with the increase in population around the world.

Approximately, 100 million people around the world need insulin, including all the people living with Type 1 diabetes and between 10-25% of people with Type 2 diabetes.

Basal insulin is the most widely used insulin among diabetic patients because of its long-acting effect. Lantus tops the market, and the segment had more than 50% market share in 2017. Many countries have come up with the biosimilars of insulin since 2015.

Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle to prevent complications.

Scope of the Report

The market is segmented by product (lantus, levemir, tresiba, toujeo, basaglar, and biosimilar glargines) and geography.

Key Market Trends - Insulin Glargine Market Access has Widened

Lantus (insulin glargine) is the first long-acting insulin brought into the market by Sanofi. The product was approved for medical use in the United States in 2000.

Lantus’ reach was high among patients across different geographical regions, and it is one of the most top-selling drugs for Sanofi, which is exported to more than 100 countries.

As of 2015, Lantus market share was around USD 7 billion. However, patent protection for Lantus expired in most countries in 2015. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the United States) and Abasaglar (as a biosimilar in the European Union).

In 2015, Sanofi launched the extended version of Lantus as Toujeo with 300U/mL strength.

In less stringent regulatory environments, such as India, China, Mexico, and Peru, several biosimilar insulin already exist at lower prices. In India, a glargine biosimilar was first introduced by Biocon in 2011 at a cost that was 40% lower than Lantus. More recently, Lupin Ltd, in agreement with LG Life Sciences, launched its biosimilar ‘Basugine’ in 2014.

In China, follow-on biologics Basalin (Gan and Lee Pharmaceuticals, Beijing) ranked second in the Chinese glargine market, and occupied a 40% share, after Lantus, in 2017.

The United States Leads the Global Basal Insulin Market

In the global basal insulin market, the United States held 65.6% market share in 2017. Lantus is the top-selling drug in the country and occupies 49% market share, followed by Levemir, Tresiba, Toujeo, and Basaglar.

The sale of Lantus is expected to decrease during the forecast period, due to the presence biosimilars Basaglar and Toujeo (which are the extended versions of Lantus).

The other biosimilar of Lantus (insulin glargine) is Lusduna from Merck, which was tentatively approved by the FDA in the United States. However, despite a favorable nod from the FDA, Merck decided to discontinue Lusduna because of “anticipated pricing and cost of production”.

Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2019-2024) due to its ultra-long-acting effect. The levemir segment is decreasing due to the switch of patients to Tresiba.

Competitive Landscape

The global basal insulin market is consolidated, with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers.

Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).

Biocon collaborated with Mylan to develop Semglee (insulin glargine biosimilar).
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biocon
  • Eli Lilly
  • Exir
  • Julphar
  • Novo Nordisk AS
  • Sanofi Aventis
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.1.1.1 Lantus
5.1.1.2 Levemir
5.1.1.3 Toujeo
5.1.1.4 Tresiba
5.1.1.5 Basaglar
5.1.1.6 Insulin Glargine Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)

6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk AS
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Julphar
7.1.6 Exir
7.1.7 SEDICO
7.1.8 Wockhardt
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novo Nordisk AS
  • Sanofi Aventis
  • Eli Lilly
  • Biocon
  • Julphar
  • Exir
  • SEDICO
  • Wockhardt
Note: Product cover images may vary from those shown
Adroll
adroll